Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 1998

View Archived Issues

Medtronic announces another merger agreement

The Medicines Company begins phase III testing of Hirulog in heart attack patients

Immune Response receives broader patent protection for RA vaccine technology

Micrologix Biotech initiates phase I trial in U.S. with MBI-226

MGI Pharma expands prostate cancer study with MGI-114

Phase II trial of diabetic neuropathy Rx commenced by Myelos

Toray discloses new epsilon opioid receptor ligands

New antitumor series developed at Daiichi

Carbostyril compounds useful for arteriosclerosis and thrombosis

Wide series of adenosine kinase inhibitors undergoing evaluation at Abbott

News from ASH: lisofylline in BMT

Orally bioavailable anti-HIV peptides described in patent literature by Japan Energy

In vitro and clinical study results support development of nitazoxanide for H. pylori infection

Preliminary indications support safety and efficacy of 90Y-labeled lintuzumab in AML

Pfizer produces novel erythromycins using precursor-directed biosynthetic technology

Broad-spectrum, water-soluble antiviral agent produced by Streptomyces discovered in Japan

New imaging agent using AnorMED technology begins phase III trials

Avigen presents results of preclinical testing of hemophilia gene therapy and plans clinical trials

HBV DNA vaccine elicits protective immune response in humans for first time

Combination tablet that eases pill burden in HIV therapy now available in Canada

ImClone's anti-KDR antibody, a novel angiogenesis inhibitor, featured at ASH

Idec further defines clinical usage of IDEC-Y2B8

Canadian approval obtained for first chickenpox vaccine

The FDA approves lamivudine for the treatment of chronic HBV

Thalidomide evaluated for toxic epidermal necrolysis and found detrimental

Biological activity of ZD-7944 characterized in vitro and in animals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...